Do analysts recommend SPRB or IZTC?

Spruce Biosciences currently has a consensus price target of $159.50, suggesting a potential upside of 176.38%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, SPRB or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Spruce Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spruce Biosciences $4.91M 33.73 -$38.97M -$39.78 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is SPRB or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -123.53% -90.35% Invizyne Technologies N/A N/A N/A

Do analysts rate ADAG or IZTC?

Adagene presently has a consensus target price of $10.00, indicating a potential upside of 171.00%. Given Adagene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Adagene is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, ADAG or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 31.78 -$17.61M N/A N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is ADAG or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Invizyne Technologies N/A N/A N/A

Do analysts recommend IZTC or CRBU?

Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 393.63%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has better valuation & earnings, IZTC or CRBU?

Invizyne Technologies has higher earnings, but lower revenue than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Caribou Biosciences $11.16M 15.08 -$148.12M -$1.08 N/A

Do analysts prefer MDWD or IZTC?

MediWound currently has a consensus target price of $33.00, suggesting a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, MDWD or IZTC?

Invizyne Technologies has lower revenue, but higher earnings than MediWound. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 10.01 -$23.88M -$1.80 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Do analysts prefer TNYA or IZTC?

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 475.29%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tenaya Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, TNYA or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is TNYA or IZTC more profitable?

Invizyne Technologies' return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -83.75% -66.53% Invizyne Technologies N/A N/A N/A

Invizyne Technologies (IZTC) Competitors

$6.79 +0.29 (+4.46%)

As of 09/2/2026

Compare

IZTC vs. SPRB, ADAG, CRBU, MDWD, and TNYA

Should you buy Invizyne Technologies stock or one of its competitors? Invizyne Technologies's main competitors and comparable companies include Spruce Biosciences (SPRB), Adagene (ADAG), Caribou Biosciences (CRBU), MediWound (MDWD), and Tenaya Therapeutics (TNYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Invizyne Technologies compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Spruce Biosciences had 11 more articles in the media than Invizyne Technologies. MarketBeat recorded 11 mentions for Spruce Biosciences and 0 mentions for Invizyne Technologies. Spruce Biosciences' average media sentiment score of 0.34 beat Invizyne Technologies' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Spruce Biosciences	Neutral
Invizyne Technologies	Neutral

Spruce Biosciences currently has a consensus price target of $159.50, suggesting a potential upside of 176.38%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Spruce Biosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Invizyne Technologies has lower revenue, but higher earnings than Spruce Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	33.73	-$38.97M	-$39.78	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

91.7% of Spruce Biosciences shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Invizyne Technologies' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Invizyne Technologies	N/A	N/A	N/A

Summary

Spruce Biosciences beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does Invizyne Technologies compare to Adagene?

Adagene (NASDAQ:ADAG) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

In the previous week, Adagene's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
Adagene	Neutral
Invizyne Technologies	Neutral

9.5% of Adagene shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Invizyne Technologies has lower revenue, but higher earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	31.78	-$17.61M	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Adagene presently has a consensus target price of $10.00, indicating a potential upside of 171.00%. Given Adagene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Adagene is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A

Summary

Adagene beats Invizyne Technologies on 7 of the 7 factors compared between the two stocks.

How does Invizyne Technologies compare to Caribou Biosciences?

Invizyne Technologies (NASDAQ:IZTC) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Caribou Biosciences had 1 more articles in the media than Invizyne Technologies. MarketBeat recorded 1 mentions for Caribou Biosciences and 0 mentions for Invizyne Technologies. Caribou Biosciences' average media sentiment score of 1.00 beat Invizyne Technologies' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Caribou Biosciences	Positive

Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 393.63%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Invizyne Technologies has higher earnings, but lower revenue than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Caribou Biosciences	$11.16M	15.08	-$148.12M	-$1.08	N/A

Invizyne Technologies has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Invizyne Technologies' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Caribou Biosciences beats Invizyne Technologies on 9 of the 12 factors compared between the two stocks.

How does Invizyne Technologies compare to MediWound?

MediWound (NASDAQ:MDWD) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

In the previous week, MediWound had 6 more articles in the media than Invizyne Technologies. MarketBeat recorded 6 mentions for MediWound and 0 mentions for Invizyne Technologies. MediWound's average media sentiment score of 0.37 beat Invizyne Technologies' score of 0.00 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Neutral
Invizyne Technologies	Neutral

46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Invizyne Technologies has lower revenue, but higher earnings than MediWound.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.01	-$23.88M	-$1.80	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has a net margin of 0.00% compared to MediWound's net margin of -170.10%. Invizyne Technologies' return on equity of 0.00% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-170.10%	-47.24%	-24.27%
Invizyne Technologies	N/A	N/A	N/A

MediWound currently has a consensus target price of $33.00, suggesting a potential upside of 149.81%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MediWound beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

How does Invizyne Technologies compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 475.29%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tenaya Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies' return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-83.75%	-66.53%
Invizyne Technologies	N/A	N/A	N/A

In the previous week, Tenaya Therapeutics had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 3 mentions for Tenaya Therapeutics and 0 mentions for Invizyne Technologies. Tenaya Therapeutics' average media sentiment score of 0.44 beat Invizyne Technologies' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Neutral
Invizyne Technologies	Neutral

Summary

Tenaya Therapeutics beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

Get Invizyne Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IZTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IZTC vs. The Competition

Export

Metric	Invizyne Technologies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.45M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.29	25.25
Price / Sales	N/A	1,342.79	623.67	97.64
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	N/A	16.39	12.92	6.14
Net Income	N/A	-$22.72M	$3.47B	$349.01M
7 Day Performance	-5.37%	0.36%	0.60%	-0.27%
1 Month Performance	47.61%	8.53%	5.72%	0.68%
1 Year Performance	-33.33%	52.66%	25.33%	14.84%

Invizyne Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IZTC Invizyne Technologies	N/A	$6.79 +4.5%	N/A	-30.0%	$42.45M	N/A	N/A	29
SPRB Spruce Biosciences	2.9018 of 5 stars	$60.78 -4.0%	$159.50 +162.4%	+671.5%	$174.68M	$4.91M	N/A	20
ADAG Adagene	3.0386 of 5 stars	$3.68 -5.6%	$10.00 +171.7%	+69.3%	$174.38M	$7.67M	N/A	260
CRBU Caribou Biosciences	1.8314 of 5 stars	$1.62 -2.4%	$7.75 +378.4%	-16.9%	$173.68M	$11.16M	N/A	100	Positive News
MDWD MediWound	2.0741 of 5 stars	$12.66 -4.4%	$33.00 +160.7%	-20.3%	$162.71M	$16.96M	N/A	80	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IZTC) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invizyne Technologies (IZTC) Competitors

IZTC vs. SPRB, ADAG, CRBU, MDWD, and TNYA

How does Invizyne Technologies compare to Spruce Biosciences?

Summary

How does Invizyne Technologies compare to Adagene?

Summary

How does Invizyne Technologies compare to Caribou Biosciences?

Summary

How does Invizyne Technologies compare to MediWound?

Summary

How does Invizyne Technologies compare to Tenaya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invizyne Technologies (IZTC) Competitors

IZTC vs. SPRB, ADAG, CRBU, MDWD, and TNYA

How does Invizyne Technologies compare to Spruce Biosciences?

Does the media prefer SPRB or IZTC?

Do analysts recommend SPRB or IZTC?

Which has preferable valuation & earnings, SPRB or IZTC?

Do institutionals and insiders hold more shares of SPRB or IZTC?

Is SPRB or IZTC more profitable?

Summary

How does Invizyne Technologies compare to Adagene?

Does the media refer more to ADAG or IZTC?

Do insiders & institutionals believe in ADAG or IZTC?

Which has preferable valuation & earnings, ADAG or IZTC?

Do analysts rate ADAG or IZTC?

Is ADAG or IZTC more profitable?

Summary

How does Invizyne Technologies compare to Caribou Biosciences?

Do institutionals & insiders have more ownership in IZTC or CRBU?

Does the media refer more to IZTC or CRBU?

Do analysts recommend IZTC or CRBU?

Which has better valuation & earnings, IZTC or CRBU?

Is IZTC or CRBU more profitable?

Summary

How does Invizyne Technologies compare to MediWound?

Does the media refer more to MDWD or IZTC?

Do institutionals & insiders believe in MDWD or IZTC?

Which has stronger earnings and valuation, MDWD or IZTC?

Is MDWD or IZTC more profitable?

Do analysts prefer MDWD or IZTC?

Summary

How does Invizyne Technologies compare to Tenaya Therapeutics?

Do institutionals and insiders have more ownership in TNYA or IZTC?

Do analysts prefer TNYA or IZTC?

Which has better earnings and valuation, TNYA or IZTC?

Is TNYA or IZTC more profitable?

Does the media prefer TNYA or IZTC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IZTC vs. The Competition

Invizyne Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools